Merck & Co., Inc. $MRK Shares Acquired by Wealth Alliance LLC

Wealth Alliance LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 33.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,028 shares of the company’s stock after buying an additional 5,760 shares during the quarter. Wealth Alliance LLC’s holdings in Merck & Co., Inc. were worth $2,770,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $25,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. in the 4th quarter valued at about $26,000. Abound Financial LLC bought a new position in Merck & Co., Inc. in the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. in the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC increased its stake in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Analysts Set New Price Targets

A number of research firms have commented on MRK. BMO Capital Markets boosted their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective on the stock. Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Bank of America boosted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, CICC Research started coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $133.94.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $131.06 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The business’s 50-day moving average price is $121.67 and its 200 day moving average price is $117.71. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $131.74. The firm has a market cap of $323.68 billion, a P/E ratio of 36.92, a PEG ratio of 5.18 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the business earned $2.22 earnings per share. The business’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.